- Home
- S vs FOLD Comparison
S vs FOLD Comparison
Compare S & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | FOLD |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.5B |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | S | FOLD |
|---|---|---|
| Price | $16.36 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 31 | 9 |
| Target Price | $19.28 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 7.5M | 2.5M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,001,278,000.00 | N/A |
| Revenue This Year | $22.84 | $20.50 |
| Revenue Next Year | $17.32 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $11.81 | $5.66 |
| 52 Week High | $21.40 | $14.50 |
Technical Indicators
Market Signals| Indicator | S | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 74.18 |
| Support Level | $16.30 | $14.21 |
| Resistance Level | $17.61 | N/A |
| Average True Range (ATR) | 0.87 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 32.25 | 100.00 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.